GlycoMimetics (NASDAQ:GLYC) Receives Neutral Rating from HC Wainwright

Posted by Anthony Miller on May 7th, 2024

HC Wainwright restated their neutral rating on shares of GlycoMimetics (NASDAQ:GLYC – Free Report) in a research report released on Monday morning, Marketbeat Ratings reports.

A number of other brokerages have also issued reports on GLYC. StockNews.com lowered shares of GlycoMimetics from a hold rating to a sell rating in a research note on Thursday, March 14th. Capital One Financial reaffirmed an overweight rating on shares of GlycoMimetics in a research note on Thursday, February 22nd.

Get Our Latest Report on GlycoMimetics

GlycoMimetics Trading Down 82.8 %

GlycoMimetics stock opened at $0.32 on Monday. GlycoMimetics has a fifty-two week low of $0.31 and a fifty-two week high of $3.53. The firm has a 50 day moving average price of $2.48 and a 200 day moving average price of $2.34.

GlycoMimetics (NASDAQ:GLYC – Get Free Report) last issued its quarterly earnings data on Wednesday, March 27th. The biotechnology company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.01. The firm had revenue of $0.01 million during the quarter. As a group, equities research analysts anticipate that GlycoMimetics will post -0.54 earnings per share for the current fiscal year.

Institutional Investors Weigh In On GlycoMimetics

Large investors have recently bought and sold shares of the stock. Acuta Capital Partners LLC acquired a new position in shares of GlycoMimetics during the third quarter worth about $41,000. MJP Associates Inc. ADV acquired a new stake in GlycoMimetics in the fourth quarter valued at approximately $238,000. Finally, Advisor OS LLC purchased a new position in GlycoMimetics in the fourth quarter worth approximately $238,000. Hedge funds and other institutional investors own 75.19% of the company’s stock.

About GlycoMimetics

(Get Free Report)

GlycoMimetics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and inflammatory diseases with unmet needs in the United States. It is developing uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat AML, as well as in phase 3 trial to treat relapsed/refractory AML.